Literature DB >> 33928430

Characterization of in vitro phase I metabolites of methamnetamine in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry.

Young-Ki Hong1, Young-Hoon Kim1, Jin-Moo Lee1, Hye Hyun Yoo2, Sun-Ok Choi1, Mi Sun Kang3.   

Abstract

N-Methyl-1-(naphthalen-2-yl)propan-2-amine (methamnetamine, PAL-1046) is an amphetamine-based new psychoactive substance (NPS). Methamnetamine has been reported to cause excessive release of serotonin, and it is classified as an empathogen or entactogen. It is not regulated as a controlled substance in most countries, and there are no studies on its metabolism. In this study, in vitro phase I metabolism of methamnetamine in human liver microsomes (HLM) and flavin-containing monooxygenase (FMO) was investigated by liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-Q-TOF/MS). Eight metabolites of methamnetamine were identified and were structurally characterized achieved by a combination of accurate mass analysis and tandem mass spectrometry. The identified metabolic processes include N-demethylation, N-hydroxylation, aromatic hydroxylation, and a combination of these processes. N-Hydroxylated metabolites were confirmed based on expressed FMOs. The major metabolite was formed from methamnetamine via hydroxylation of the naphthalene ring after the in vitro phase I process. These results could help detect methamnetamine ingestion by NPS abusers.

Entities:  

Keywords:  FMO (flavin-containing monooxygenase); HLM (human liver microsome); LC-Q-TOF/MS (liquid chromatography-quadrupole time-of-flight mass spectrometry); Metabolism; Methamnetamine; PAL-1046

Year:  2021        PMID: 33928430     DOI: 10.1007/s00414-021-02594-z

Source DB:  PubMed          Journal:  Int J Legal Med        ISSN: 0937-9827            Impact factor:   2.686


  6 in total

1.  Studies of the biogenic amine transporters. 14. Identification of low-efficacy "partial" substrates for the biogenic amine transporters.

Authors:  Richard B Rothman; John S Partilla; Michael H Baumann; Catrissa Lightfoot-Siordia; Bruce E Blough
Journal:  J Pharmacol Exp Ther       Date:  2012-01-23       Impact factor: 4.030

2.  Determination of a new designer drug, N-hydroxy-3,4-methylenedioxymethamphetamine and its metabolites in rats using ultra-performance liquid chromatography-tandem mass spectrometry.

Authors:  Ruri Kikura-Hanajiri; Maiko Kawamura; Atsuko Miyajima; Momoko Sunouchi; Yukihiro Goda
Journal:  Forensic Sci Int       Date:  2010-03-17       Impact factor: 2.395

3.  Prevalence of New Psychoactive Substances in Oral Fluid Specimens from French and Belgian Drivers: Comparison 2016/2017.

Authors:  Camille Richeval; Mélodie Nachon-Phanithavong; Vincent Di Fazio; Jean-François Wiart; Luc Humbert; Nele Samyn; Sarah Maria Richarda Wille; Delphine Allorge; Jean-Michel Gaulier
Journal:  J Anal Toxicol       Date:  2019-03-01       Impact factor: 3.367

Review 4.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

5.  Quantification of Flavin-containing Monooxygenases 1, 3, and 5 in Human Liver Microsomes by UPLC-MRM-Based Targeted Quantitative Proteomics and Its Application to the Study of Ontogeny.

Authors:  Yao Chen; Nicole R Zane; Dhiren R Thakker; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2016-02-02       Impact factor: 3.922

6.  A kinetic account for amphetamine-induced monoamine release.

Authors:  Peter S Hasenhuetl; Shreyas Bhat; Felix P Mayer; Harald H Sitte; Michael Freissmuth; Walter Sandtner
Journal:  J Gen Physiol       Date:  2018-02-09       Impact factor: 4.086

  6 in total
  1 in total

Review 1.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.